PDB4 LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS  by Ligthelm, R et al.
A402 Paris Abstracts
PDB4
LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 
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OBJECTIVES: The IMPROVE study includes results of 52,419 patient’s after 26 
weeks of treatment with biphasic insulin aspart 30/70 (BIAsp30) in routine care 
setting. The aim of this analysis was to project long-term clinical outcomes in patients 
with type 2 diabetes from the IMPROVE study switched from biphasic human insulin 
(BHI) to BIAsp30. METHODS: In total, 4,368 patients on BHI from the IMPROVE 
study were used in the present analysis. The CORE Diabetes Model was used to 
project long-term clinical outcomes based on the baseline characteristics (male 58.2%, 
mean age 57.0 years, duration of diabetes 10.7 years, HbA1c 9.2%, BMI 26.2 kg/m2 
and total daily insulin dose 32.8 IU). Patients were assumed to either continue on BHI, 
or switch to BIAsp30 and obtain the signiﬁcant (p a 0.01) treatment effects of BIAsp30 
observed in the IMPROVE study (HbA1c improvement of 1.9 percentage points, 
0.24 kg weight loss and 29.3 less major hypoglycemic events per 100 patient years). 
RESULTS: The improved glycemic control resulting from a switch from BHI to 
BIAsp30 led to a projected delay in the onset of any diabetes-related complications of 
0.7 years (2.0 versus 1.3, respectively). E.g. the projected delay of suffering a myocar-
dial infarction was 1.7 for BIAsp30 and 1.4 years BHI. The cumulative incidence of 
complications was projected to decrease with BIAsp30 in the majority of parameters 
studied, e.g. the cumulative incidence of severe vision loss was projected to decrease 
by 8.5% (1.3 %-point absolute risk reduction) and strokes by 8.6% (1.1 %-point 
absolute risk reduction). The average life expectancy was projected to increase by 1.5 
years. CONCLUSIONS: The long-term health outcome projections based on end-
points reported in the IMPROVE study indicate that switching patients with type 2 
diabetes from BHI to BIAsp30 will improve life expectancy, delay the onset of diabe-
tes-related complications, and reduce their cumulative incidence over patient 
lifetimes.
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SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 
VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS
Walczak J, Nogas G, Organa M, Przada P, Potoczny R
Arcana Institute, Cracow, Poland
OBJECTIVES: The aim of the review was to compare the efﬁcacy and safety of 
vildagliptin versus glimepiride as add-on therapy to metformin in patients with type 
2 diabetes mellitus. METHODS: The analysis was performed in accordance with the 
rules of systematic review, based on the Cochrane Collaboration (Cochrane Review-
er’s Handbook) guidelines and the Health Technology Assessment Agency in Poland 
recommendations. Literature search strategy was performed within the main medical 
databases: Medline, Cochrane Library, EMBASE, Biomed Central and CRD. 
RESULTS: one study of high quality was identiﬁed according to predeﬁned selection 
criteria. The trial evaluated ﬁfty-two-week effectiveness of vildagliptin plus metformin 
versus glimepiride plus metformin. The analysis disclosed non inferior efﬁcacy of 
intervention and comparator in HbA1c reduction. The change in fasting plasma 
glucose was also comparable between groups. Patients in vildagliptin group more fre-
quently reached a target HbA1c level of 7% without hypoglycaemia (50.9% of par-
ticipants) than patients in glimepiride group (44.3% of participants). Furthermore 
vildagliptin was more efﬁcient in body weight reduction; WMD  1.79 (95% CI: 
2.11; 1.47). The risk of hypoglycaemia episodes was higher within glimepiride 
therapy; RR  0.10 (95% CI: 0.07; 0.16). Vildagliptin treatment resulted in lower 
incidence of adverse events, serious adverse events and discontinuation because of 
adverse events (respectively 74.5%, 7.1%, and 4.8% in vildagliptin group versus 
81.1%, 9.5%, and 7.7% in glimepiride group). The risk of cardiovascular complica-
tions was higher in comparative group but it was not statistically signiﬁcant. Dizziness, 
fatigue, asthenia, tremor, hyperhidrosis and hunger were signiﬁcantly less frequent in 
vildagliptin group. CONCLUSIONS: Vildagliptin as add-on therapy to metformin is 
more efﬁcient and safer technology than glimepiride combined with metformin in the 
treatment of type 2 diabetes mellitus.
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ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE 
COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL 
NEUROPATHY
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Oral administration of the combination prescription product containing L-methylfo-
late, pyridoxal-5’-phosphate, and methylcobalamin (MPM) has shown to increase 
epidermal nerve ﬁber density in humans, reduce neuropathic pain and restore sensa-
tion in patients with diabetic neuropathy (DPN). It is believed to increase vascular 
perfusion through lowering homocysteine and increasing nitric oxide levels. OBJEC-
TIVES: Evaluate the clinical and economic impact of orally-administered MPM on 
patients with diabetic peripheral neuropathy (DPN) in a managed care setting. 
METHODS: Data were obtained from the 30 million member HealthCore Integrated 
Research Databaseä. Patients with at least 1 claim for diabetes, antidiabetic agents 
and DPN and q2 claims for MPM between July 1, 2004 and April 30, 2007, with q6 
months pre and q12 months post index eligibility were matched 2:1 on age, gender 
and health plan region with non-MPM treated patients. Cost comparisons were per-
formed on the population 65 years old to assure full capture of health care costs. 
RESULTS: A total of 89 MPM treated patients and 178 matched controls were identi-
ﬁed, 65% were male and mean (SD) age was 60.1 (o9.3) years. MPM treated patients 
were more likely to be treated with anticonvulsants in the pre-index period (p  0.01). 
There was a 31% reduction in the use of anticonvulsants post-index for the MPM 
group and a 10% reduction in the control group. There was a meaningful albeit non-
signiﬁcant cost difference in the 12 month post-index DPN related costs between the 
65 year old MPM and control groups ($1029 n  56 vs. $1401 n  112). CONCLU-
SIONS: This observational cohort study demonstrated a reduction in the use of anti-
convulsant medication among the MPM cohort, perhaps denoting a reduction in the 
need for pain medication, and costs related to DPN were lower in the MPM group. 
Additional randomized controlled trials need to be conducted to validate these 
results.
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THE CLINICAL EFFECTIVENESS OF SOMATROPIN (GENOTROPIN®) IN 
CHILDREN WITH SHORT STATURE: A SYSTEMATIC REVIEW
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OBJECTIVES: Genotropin® is a brand of somatropin (human growth hormone [GH]) 
licensed for the treatment of children with short stature due to: growth hormone 
deﬁciency (GHD), Prader-Willi syndrome (PWS), Turner syndrome (TS), chronic renal 
insufﬁciency (CRI) and those born small for gestational age (SGA). Although ﬁnal 
height (FH) is probably the most effective outcome for measuring somatropin effective-
ness, there is a lack of randomised controlled trial (RCT) data reporting FH and other 
important outcomes, such as quality of life (QoL) which is rarely reported for children. 
The objective of this systematic review (SR) of RCTs and observational studies was 
to investigate the efﬁcacy and safety of Genotropin in children with these indications, 
and identify whether the lack of relevant RCT data in this therapy area can be sup-
plemented with observational studies. METHODS: Predeﬁned search terms were used 
to search eight electronic databases, including Medline and Embase, for published 
English language studies. Additionally, bibliographies of included articles were exam-
ined for relevant studies. RCTs or observational studies were retrieved if they included 
a population of children (16 years) with GHD, PWS, TS, CRI or SGA treated with 
Genotropin. The main reported outcome measures included FH and short-term 
growth responses, e.g. growth velocity. RESULTS: Thirty RCTs and 37 observational 
studies were identiﬁed. No RCTs were identiﬁed that included data on QoL. One RCT 
and 11 observational studies reported data for FH. FH was consistently improved 
following treatment with Genotropin. Seven of the observational studies were based 
on data sourced from the Pﬁzer International Growth Survey (KIGS), which showed 
signiﬁcant gains of up to 2.3 height standard deviation scores. CONCLUSIONS: This 
SR reveals the paucity of long-term RCTs reporting data on FH and QoL in children, 
thus highlighting the consequent importance of observational studies of GH therapy, 
such as KIGS, which reports FH.
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OBJECTIVES: Diabetes mellitus (DM) is a worldwide problem. Data regarding the 
utilization pattern of antidiabetics is lacking in Malaysia. The present study evaluated 
the prescribing trends of antidiabetic drugs in a university health care centre in Malay-
sia during the years 2002 and 2003. METHODS: Retrospective data for 2002 and 
2003 was collected from the USM Center for Knowledge, Communication and Tech-
nology. A drug utilization study using the Anatomical Therapeutic Chemical classiﬁca-
tion and deﬁned daily doses (ATC/DDD) methods was conducted. Selected drug use 
indicators as suggested by WHO/INRUD were used in this study. Prescribing preva-
lence was expressed by the DDD methodology. The utilization of antidiabetic drugs 
was expressed as the number of deﬁned daily doses per 1000 inhabitants per day 
(DDD/1000/day). RESULTS: The number of antidiabetic patients was 300. Total 
1289 and 1565 prescription data were collated from the database for the years 2002 
and 2003, respectively. The total number of different drugs prescribed in 2002 and 
2003 were 2982 and 3345, respectively. Among these, 1997 (67.0%) of drugs pre-
scribed in 2002 and 2389 (71.4%) of drugs prescribed in 2003 were antidiabetics. In 
general, the consumption of antidiabetics in USM Heath Centre increased from 3.4 
DDD/1000/day in 2002 to 4.7 DDD/1000/day in 2003. Signiﬁcant antidiabetic pre-
scribing patterns related to metformin and gliclazide were observed in this study. 
Metformin was the most commonly prescribed drug while gliclazide was the most 
consumed drug. CONCLUSIONS: It is reasonable to conclude that diabetic medicine 
utilization is on increase. Much attention and effort should be directed towards 
establishing the burden of diabetes in USM in economic terms.
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IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES 
CARE FOR USERS OF ROSIGLITAZONE
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OBJECTIVES: To understand the impact of the May 2007 safety warning about 
rosiglitazone from the US Food and Drug Administration (FDA) on the subsequent 
